RNA sequence-specific mediators of RNA interference
The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response. This specific targeting of a particular gene function is useful in functional genomic and therapeutic applications.
1. A knockdown mammalian cell or non-human mammalian organism comprising a double-stranded RNA molecule of from about 21 to 23 nucleotides that targets an mRNA for degradation in the cell or organism, wherein the RNA molecule is a chemically synthesized RNA or an analog of naturally occurring RNA, wherein the RNA molecule differs from a naturally occurring RNA by addition, deletion, substitution, or alteration of one or more nucleotides, and wherein the RNA molecule comprises a strand that is perfectly complementary to the mRNA.
2. A eukaryotic cell comprising a double-stranded RNA molecule of from about 21 to 23 nucleotides that targets an mRNA for degradation in the cell, wherein the RNA molecule is a chemically synthesized RNA or an analog of naturally occurring RNA, wherein the RNA molecule differs from a naturally occurring RNA by addition, deletion, substitution, or alteration of one or more nucleotides, and wherein the RNA molecule comprises a strand that is perfectly complementary to the mRNA to mediate RNA interference of the mRNA.
3. The cell of claim 2 , wherein the RNA molecule comprises one or more non-naturally occurring nucleotides.
4. The cell of claim 3 , wherein the RNA molecule comprises one or more non-standard nucleotides.
5. The cell of claim 2 , wherein the RNA molecule comprises one or more deoxyribonucleotides.
6. The cell of claim 2 , wherein the RNA molecule is a chemically synthesized RNA molecule.
7. The cell of claim 2 , wherein the RNA molecule is an analog of a naturally occurring RNA.
8. The cell of claim 2 , wherein the alteration comprises addition of a non-nucleotide material to one or both ends of the RNA molecule.
9. The cell of claim 2 , wherein the RNA molecule comprises a strand that has sufficient sequence correspondence to the mRNA to direct cleavage of the mRNA to which the sequence corresponds.
10. The cell of claim 9 , wherein the sufficient sequence correspondence to the mRNA is determined using a Drosophila lysate in vitro assay.
11. The cell of claim 9 , wherein the sufficient sequence correspondence to the mRNA is determined using a translation-based RNAi assay.
12. The cell of claim 2 , wherein a strand of the RNA molecule is about 21 nucleotides in length.
13. The cell of claim 2 , wherein a strand of the RNA molecule is from 21 nucleotides to 23 nucleotides in length.
14. The cell of claim 2 , wherein each strand of the RNA molecule is about 21 nucleotides in length.
15. The cell of claim 2 , wherein each strand of the RNA molecule is from 21 nucleotides to 23 nucleotides in length.
16. The cell of claim 2 , wherein the RNA molecule comprises two separate strands which are not covalently linked.
17. The cell of claim 2 , wherein the RNA molecule comprises a terminal 3′ hydroxyl group.
18. The cell of claim 2 , wherein the mRNA is a cellular mRNA.
19. The cell of claim 2 , wherein the mRNA is a mammalian mRNA.
20. The cell of claim 2 , wherein the mRNA is a human mRNA.
21. The cell of claim 2 , wherein the mRNA encodes a protein whose presence is associated with a disease or an undesirable condition.
22. The cell of claim 2 , wherein the mRNA is a viral mRNA.
23. The cell of claim 2 , wherein the mRNA encodes an oncoprotein.
24. A eukaryotic cell comprising an RNA molecule of from about 21 to 23 nucleotides that mediates RNA interference of an mRNA in the cell, wherein the RNA molecule comprises:
(a) one or more non-naturally occurring nucleotides; and
(b) a sense strand and an antisense strand, wherein the antisense strand that is perfectly complementarity to the mRNA to mediate RNA interference of the mRNA.